


# PHARMACEUTICALS



## MARKET SIZE

Indian Pharmaceutical Market (US\$ billion)




Note: P-Projected



## SECTOR COMPOSITION

R&D Investment by Indian Pharma Companies\* (% of sales)




Note: \*Top 10 companies as per research by HDFC Securities




## KEY TRENDS


Pharmaceutical Export from India (US\$ billion)



Government Expenditure on Health in India (US\$ billion)



Note: E-Estimate



## GOVERNMENT INITIATIVES



Pradhan Mantri Bhartiya  
Janaushadhi Pariyojana  
(PMBJP)



COVID BEEP



National Health Policy



## ADVANTAGE INDIA

- Cost Efficiency:** India has emerged as the medical tourism hub of the world providing cost-effective treatments with the latest technology enabled by several pathbreaking reforms and provisions in healthcare sector. Access to affordable HIV treatment from India is one of the greatest success stories in medicine. India is one of the biggest suppliers of low-cost vaccines in the world, thereby rightly making it the 'Pharmacy of the World'.
- Economic Drivers:** The total market size of the Indian Pharma Industry is expected to reach US\$ 130 billion by 2030 and US\$ 450 billion market by 2047. The domestic pharmaceutical industry would likely reach US\$ 57 billion by FY25 and see an increase in operating margins of 100-150 basis points (bps). Indian pharmaceutical companies are projected to achieve a revenue growth of 9-11% in FY25. India's medical technology industry is poised to reach exports of up to US\$ 20 billion (Rs. 1,69,000) by FY30.
- Policy support:** The PLI scheme for pharmaceuticals is being implemented with a total outlay of the Rs. 15,000 crore (US\$ 2.04 billion) spanning from 2020-21 to 2028-29, to boost India's manufacturing capacity, elevate investment, and diversify product offerings in the sector. Through Pradhan Mantri Bhartiya Jan Aushadhi Kendras (PMBJKs) government has set a target to increase the number of PMBJKs to 10,500 by the end of March 2025. Product basket of PMBJP comprises of 1,451 drugs and 240 surgical instruments. The Union Cabinet, on April 26, 2023, approved the National Medical Devices Policy, 2023. The Indian government disbursed Rs. 604 crore (US\$ 69.76 million) under the Production-Linked Incentive (PLI) scheme for the pharma sector during H1 of FY25.
- Increasing Investments:** The FDI equity inflow in the Drugs and Pharmaceuticals industry is Rs. 2,00,166 crore (US\$ 23.41 million) during the period April 2000-March 2025. The Union Budget 2025-26 proposes to allocate Rs. 5,268.72 crore (US\$ 602.90 million) for the Department of Pharmaceuticals (DoP), around 28.8% higher than the Rs. 4,089.95 crore (US\$ 468.01 million) Budget Estimates (BE) for the FY25.